www.hepqld.asn.au FAREWELL TO LOU REED VOLUME 10, DEC 2013

First Page		Document Content
Date: 2013-12-18 21:46:57 Hepatitis Biology Protease inhibitors Viruses Viral hepatitis Telaprevir Boceprevir Hepatitis C Interferon Medicine Health Antivirals		www.hepqld.asn.au FAREWELL TO LOU REED VOLUME 10, DEC 2013 Add to Reading List Source URL: hepqld.asn.au Download Document from Source Website File Size: 1,58 MB Share Document on Facebook

	PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno DocID: 1vlwz - View Document
	IMPORTANT PLEASE READ PART III: CONSUMER INFORMATION INTRON A® interferon alfa-2b This leaflet is part III of a three-part "Product Monograph" DocID: 1uNBi - View Document
	Evaluation of Interferon-gamma-Producing T Cells DocID: 1uFKZ - View Document
	PRODUCT MONOGRAPH INTRON A® interferon alfa-2b Lyophilized Powder with Diluent: 10 million IU interferon alfa-2b/vial DocID: 1umTG - View Document
	  Data Sheet Recombinant Human Interferon-gamma (rh IFN-) Preclinical Grade - Order No.: µg) DocID: 1u1rK - View Document